Ruiz GM, Hernández ABG, Herrera MP, Camacho ME, Urrutia OM, Sánchez MAE, Rosales PG, Dávila ML

Language: Spanish
References: 22
Page: 345-352
PDF size: 212.13 Kb.

ABSTRACT

Background: During the coronavirus pandemic, various neurological manifestations have been reported. The pediatric population is affected less frequently and seriously.
Objective: To evaluate the association between acute neurological symptoms in pediatric patients with confirmed COVID - 19 infection.
Design: Case series of patients with acute neurological symptoms temporarily associated with SARS-CoV-2 infection; Patients younger than 17 years of age with Guillainacute symptoms such as ascending weakness with areflexia, decreased visual acuity, encephalopathy, ischemic cerebrovascular event, or muscle weakness with elevations of plasma creatinine kinase (CK) were evaluated.
Results: In this study, 23 patients with neurological symptoms who attended the emergency room consecutively over a period of 4 months were evaluated. 10 had a history of contact or infection with SARS-CoV-2. There were 5 men from 2 to 16 years old (mean age 11.6), 4 of them had contact with a relative who presented SARS-CoV-2, and 2 had respiratory symptoms related to the disease of SARS-CoV-2 in the two weeks prior to the onset of neurological symptoms related to the following pathologies: Optic neuritis ((n = 2), Guillain-Barré syndrome (n = 3), myositis with rhabdomyolysis (n = 1), ischemic vascular event (n = 2) , acute cerebellitis (n = 1), and Anti NMDA-R encephalitis (n = 1).
Conclusions: Neurological manifestations temporarily associated with COVID- 19 infections are present in the pediatric population even in the absence of respiratory symptoms. COVID-19 infection should be considered as an etiology in patients with neurological symptoms, especially if there is a history of contact with a confirmed case.

REFERENCES

1. Wu F, Zhao S, Yu B, Chen YM, et al. A new coronavirusassociated with human respiratory disease in China. Nature 2020; 579: 265-269. https://doi.org/10.1038/s41586-020-2008-3.

2. Orsucci D, Caldarazzo-Ienco E, Nocita G, Napolitano A, etal. Neurological features of COVID-19 and their treatment:a review, Drugs Context, 2020; 9:1-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295105/

3. Hoang A, Chorath K, Moreira A, Evans M, et al. COVID-19 in 7780 pediatric patients: A systematic review.EClinicalMedicine 2020; 26; 24: 100433. Doi: 10.1016/j.eclinm.2020.100433.

4. Dong Y, Mo X, Hu Y, Qi X, et al. Epidemiology of COVID-19Among Children in China. Pediatrics 2020; 145 (6):e20200702. Doi: 10.1542/peds.2020-0702.

5. Abdel-Mannan O, Eyre M, Löbel U, Bamford A, et al .Neurologic and Radiographic Findings Associated WithCOVID-19 Infection in Children. JAMA Neurol 2020; 1; 77(11): 1440-1445.

6. Sanket S, Danda D, Kavadichanda C, Das S, et al. Autoimmuneand rheumatic musculoskeletal diseases as aconsequence of SARS-CoV-2 infection and its treatment.Rheumatol Int 2020; 40 (10): 1539-1554. Doi: 10.1007/s00296-020-04639-9.

7. Paybast S, Gorji R, Mavandadi S. “Guillain-Barré Syndromeas a Neurological Complication of Novel COVID - 19 Infection:A Case Report and Review of the Literature,” Neurologist2020; 25 (4): 101-103.

8. Toscano G , Palmerini F , Ravaglia S, Ruiz L,et al. “Guillain–Barré Syndrome Associated with SARS-CoV-2.” N Engl JMed 2020; 382 (26): 2574-2576.

9. Agosti E, Giorgianni A, D'Amore F, Vinacci G, et al. IsGuillain-Barrè syndrome triggered by SARS-CoV-2? Casereport and literature review. Neurol Sci 2021; 42 (2): 607-612. Doi: 10.1007/s10072-020-04553-9.

10. Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B.Guillain-Barré syndrome during SARS-CoV-2 pandemic:A case report and review of recent literature. J PeripherNerv Syst. 2020; 25 (2): 204-207. Doi: 10.1111/jns.12382.

11. Sedaghat Z, Karimi N. Guillain Barre syndrome associatedwith COVID-19 infection: A case report. J Clin Neurosci2020; 76: 233-235. Doi: 10.1016/j.jocn.2020.04.062.

12. Tenembaum S, Chitnis T, Nakashima I, Collongues N, et al.Neuromyelitis optica spectrum disorders in children andadolescents. Neurology 2016; 87 (Suppl 2): S59-66. Doi:10.1212/WNL.0000000000002824.

13. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses andOcular Implications in Humans and Animals. Ocul ImmunolInflamm 2020; 28 (3): 391-395.

14. Cyr DG, Vicidomini CM, Siu NY, Elmann SE. Severe BilateralVision Loss in 2 Patients With Coronavirus Disease 2019.J Neuroophthalmol 2020; 40 (3): 403-405. Doi: 10.1097/WNO.0000000000001039.

15. Romero-Sánchez CM, Díaz-Maroto I, Fernández-DíazE, Sánchez-Larsen Á, et al Neurologic manifestations inhospitalized patients with COVID-19: The ALBACOVID registry. Neurology 2020; 95 (8): e1060-e1070. Doi: 10.1212/WNL.0000000000009937.

16. Divani AA, Andalib S, Di Napoli M, Lattanzi S, CoronavirusDisease 2019 and Stroke: Clinical Manifestations andPathophysiological Insights. J Stroke Cerebrovasc Dis2020; 29 (8): 104941. Doi: 10.1016/j.jstrokecerebrovasdis.2020.104941.

17. Ribes A, Vardon-Bounes F, Mémier V, Poette M, et al Thromboembolicevents and Covid-19. Adv Biol Regul 2020; 77:100735. Doi: 10.1016/j.jbior.2020.100735.

18. Montalvan V, Lee J, Bueso T, De Toledo J, et al. Neurologicalmanifestations of COVID-19 and other coronavirus infections:A systematic review. Clin Neurol Neurosurg 2020;

19. 194: 105921. Doi: 10.1016/j.clineuro.2020.105921.19. Mao L, Jin H, Wang M, Hu Y, et al Neurologic Manifestationsof Hospitalized Patients With Coronavirus Disease 2019 inWuhan, China. JAMA Neurol 2020; 77 (6): 683-690. Doi:10.1001/jamaneurol.2020.1127.

20. Ellul MA, Benjamin L, Singh B, Lant S, et al. “Neurologicalassociations of COVID – 19.” Lancet Neurol 2020; 19 (9):767-783.

21. Gefen AM, Palumbo N, Nathan SK, Singer PS, et al. PediatricCOVID-19-associated rhabdomyolysis: a case report.Pediatr Nephrol 2020; 35 (8): 1517-1520. Doi: 10.1007/s00467-020-04617-0.

22. Monti G, Giovannini G, Marudi A, Bedin R, et al.“Anti-NMDAreceptor encephalitis presenting as new onset refractorystatus epilepticus in COVID – 19.” Seizure 2020; 81: 18-20.